Tempus AI Stock Climbs As ARK, Medtronic, Gilead Back Growth Story

Tempus AI Inc. surged as pivotal clinical AI partnership news fueled investor optimism, with stocks have been trading up by 6.42 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Positive joint trial with Medtronic showed TEM’s AI notification platform boosted heart valve surgeries by 40% and specialist evaluations by 27% across 35 hospitals, sending shares up about 4.3%.
Expanded multiyear deal with Gilead gives the pharma giant enterprise-wide access to Tempus AI’s Lens platform and oncology datasets, reinforcing the long-term data monetization story.
ARK Invest, led by Cathie Wood, is rotating out of mega-cap tech and semis into TEM, making Tempus AI one of ARK’s largest positions despite a >20% year-to-date slide.
A William Blair pre‑Q1 diagnostics call underscores rising institutional focus on the testing and AI‑driven diagnostics space where TEM is trying to scale.

Live Update At 10:03:05 EDT: On Wednesday, April 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 6.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI, trading under ticker TEM, is behaving like a classic high-growth, high-loss story on the chart and in the financials. On 2026/04/15, TEM closed at $52.75, up from $49.53 the prior day and continuing a sharp rebound from the 2026/04/10 low near $42.94. That’s a nearly 23% bounce in just a few sessions, fueled by strong news and aggressive dip buying.

Intraday, TEM showed steady demand. The stock opened around $50.38 and pushed over $53.00, with buyers stepping in on every small pullback. That tells traders momentum funds and short-term players are active.

More Breaking News

Fundamentally, Tempus AI generated about $1.27B in revenue over the last year, but it is still deeply unprofitable. EBIT margin sits around -17.6%, and profit margin is roughly -19%. Cash flow from operations for the latest quarter was about -$36.8M, with free cash flow near -$43.1M. The balance sheet, however, shows a cash and short-term investment pile of roughly $755M and a solid current ratio of 3.1, giving TEM time to execute. For traders, that mix—strong top-line, steep losses, but ample cash—is the textbook setup for volatile, news-driven trading.

Why Traders Are Watching TEM Right Now

Tempus AI is finally giving traders something concrete to trade beyond the “AI in healthcare” buzzwords. The headline driver is the Medtronic clinical trial. TEM’s automated AI notification platform for severe heart valve disease didn’t just look good on a slide deck; it actually changed treatment patterns in the real world. A 40% jump in surgical interventions and a 27% increase in specialist evaluations across 35 hospitals is serious, behavior-changing data. The market noticed, and TEM popped roughly 4.3% on that news.

For active traders, that kind of clinical validation matters. It suggests hospitals may be willing to pay for Tempus AI tools because they improve outcomes and workflow. That can translate into recurring software and data revenue. Every time TEM proves its AI can move the needle in real clinical settings, the bull case gets a little more tangible.

Then comes the Gilead expansion. By giving Gilead Sciences enterprise-wide access to the Tempus Lens AI platform and de‑identified multimodal oncology datasets, TEM is embedding itself into pharma R&D pipelines. Traders should see this as a long-duration revenue stream: data access fees, platform usage, and potential project expansions as Gilead relies more on Tempus AI engines.

Layer ARK Invest on top. Cathie Wood is rotating capital out of mega-cap tech and semis into TEM, making Tempus AI one of ARK’s bigger positions even after a >20% year-to-date drawdown. That kind of high-conviction sponsorship often attracts momentum traders. It also raises volatility. When a fund builds a heavy position, every headline—good or bad—can amplify moves in TEM.

Finally, the William Blair pre‑Q1 call on diagnostics and testing highlights that the entire space is under the microscope. If sentiment tilts bullish on AI‑driven diagnostics, TEM is one of the pure-play tickers traders will crowd into.

Conclusion

Tempus AI is acting like a momentum name with real catalysts behind the move. The chart shows TEM breaking out from the low-$40s back into the low-$50s in a straight, powerful leg, backed by heavy news flow. The Medtronic trial proves that Tempus AI platforms can push doctors to act faster and more often in severe heart valve disease. The expanded Gilead partnership tells traders that big pharma wants deeper access to Tempus AI data and tools. ARK’s rotation into TEM reinforces the narrative that AI‑powered precision medicine is where the next big value layer may develop.

None of this erases the fundamental risks. Tempus AI is still losing money, with negative margins and heavy cash burn, even though the company is sitting on hundreds of millions in cash and short-term investments. That’s why TEM trades like a rollercoaster—huge upside on good news, ugly drawdowns when sentiment sours.

For active traders, the playbook stays the same: treat TEM as a catalyst-driven, high‑beta name, not a sleepy healthcare stock. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.”. Watch how price reacts around any new data readout, pharma deal, or conference commentary. As Tim Sykes likes to say, “The pattern tells you the odds, the catalyst tells you the timing, but risk management decides whether you stick around long enough to benefit.” With TEM, the story is getting stronger, but smart trading rules still matter most.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!